Kidney impairment may change how MK-8527 works in the body
NCT ID NCT06295796
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at how the drug MK-8527 is processed in people with moderate or severe kidney impairment compared to healthy volunteers. Eighteen participants received a single oral dose, and researchers measured drug levels in the blood over time. The goal was to understand how kidney function affects the drug's behavior, not to test any treatment effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MK-8527
- What this could lead to
- If successful, this study could help doctors determine the right dose of MK-8527 for patients with kidney problems.
- What could go wrong
- This is a very early, small study (18 participants) focused on drug levels, not on treating any disease. It does not test whether MK-8527 works for any condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research by Design ( Site 0001)
Chicago, Illinois, 60643, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a damaged kidney change how antibiotics work?
- Can kidney health change how a new drug works?
- Kidney function may change how D-2570 works in the body
- Sleep drug YZJ-1139 put to the test in kidney patients
- Kidney function may change how antibiotic levornidazole acts in the body
- Kidney health may change how this drug works